Managed care
Southern California Permanente Medical Group
Southern California Permanente Medical Group was paid $29.70M by Medicaid between Jan 2018 and Dec 2024, across 297 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 21% of everything it billed.
33Billing provider infoSOUTHERN CALIFORNIA PERMANENTE MEDICAL GROUP
LOS ANGELES, CA 90034
LOS ANGELES, CA 90034
33aNPI1043242563assigned 07/07/2006
33bProvider typeHealth Maintenance Organization
28Total paid$29.70M
24GClaims885,502
24DCodes billed297
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Health Maintenance Organization providers in California
Rank by total paid#8 of 151
Median peer was paid$59K
This provider vs. median503×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DAVIDOFF, RAMIN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 90,190 | $251K | |
| 2019 | 120,811 | $594K | |
| 2020 | 80,530 | $2.12M | |
| 2021 | 111,654 | $4.02M | |
| 2022 | 121,910 | $4.44M | |
| 2023 | 158,372 | $7.48M | |
| 2024incomplete | 202,035 | $10.79M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 90,555 | 89,134 | $6.20M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 53,014 | 52,257 | $4.84M |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 4.2% | 22,243 | 21,756 | $1.25M |
| 91320 | 3.5% | 6,243 | 6,239 | $1.03M | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.5% | 74,230 | 72,231 | $1.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.4% | 9,500 | 9,395 | $1.01M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.4% | 5,659 | 4,355 | $1.00M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 3.3% | 19,725 | 14,646 | $988K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.7% | 19,370 | 19,004 | $793K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.8% | 2,555 | 1,658 | $545K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.8% | 74,032 | 73,807 | $528K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.7% | 20,411 | 11,837 | $504K |
285 more codes
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | 1.6% | 465 | $465K |
| 67028 | Intravitreal injection of a pharmacologic agent | 1.5% | 2,190 | $433K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 13,747 | $406K |
| 90480 | 1.4% | 7,932 | $401K | |
| 90662 | 1.3% | 3,674 | $400K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 4,353 | $394K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.2% | 24,774 | $371K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 4,383 | $359K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 6,807 | $325K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 2,913 | $259K |
| 77080 | <1% | 7,858 | $238K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 593 | $209K |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | <1% | 89 | $208K |
| 11721 | <1% | 1,874 | $202K | |
| 71045 | Radiologic examination, chest; single view | <1% | 35,282 | $193K |
| 99442 | <1% | 2,438 | $172K | |
| 0001A | <1% | 4,198 | $162K | |
| 0002A | <1% | 4,067 | $158K | |
| 92002 | <1% | 4,422 | $153K | |
| 90686 | <1% | 29,501 | $151K | |
| 20610 | <1% | 1,255 | $144K | |
| 0064A | <1% | 3,014 | $124K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 7,392 | $123K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 4,298 | $117K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 6,338 | $112K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13,346 | $108K |
| 99441 | <1% | 2,753 | $105K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,198 | $98K |
| 99223 | Prolong inpt eval add15 m | <1% | 1,052 | $93K |
| 0012A | <1% | 2,412 | $90K | |
| 0124A | <1% | 2,560 | $89K | |
| 92134 | <1% | 3,251 | $85K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 8,874 | $83K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 6,363 | $82K |
| 0011A | <1% | 2,209 | $80K | |
| 69210 | <1% | 1,028 | $79K | |
| 99443 | <1% | 830 | $76K | |
| 73562 | <1% | 4,180 | $74K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,544 | $73K |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | <1% | 20 | $72K |
| J0178 | Injection, aflibercept, 1 mg | <1% | 26 | $67K |
| 90837 | Psychotherapy session, about an hour | <1% | 2,352 | $67K |
| 96415 | <1% | 628 | $64K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,372 | $63K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,483 | $63K |
| 92557 | <1% | 1,690 | $62K | |
| 0004A | <1% | 1,534 | $61K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 3,480 | $60K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,152 | $60K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 908 | $58K |
| 0134A | <1% | 1,530 | $57K | |
| 92551 | <1% | 23,691 | $56K | |
| 0054A | <1% | 1,334 | $56K | |
| 97161 | <1% | 756 | $55K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 862 | $50K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 480 | $49K |
| 72100 | <1% | 2,002 | $49K | |
| 73630 | <1% | 4,216 | $49K | |
| 90750 | <1% | 534 | $46K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 2,611 | $45K |
| 73030 | <1% | 2,363 | $45K | |
| 92567 | <1% | 2,912 | $42K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 2,528 | $42K |
| 0071A | <1% | 1,009 | $41K | |
| 92015 | Determination of refractive state | <1% | 4,858 | $39K |
| 0072A | <1% | 809 | $32K | |
| 95800 | <1% | 153 | $32K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 63 | $29K |
| 76641 | <1% | 1,055 | $29K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 12,072 | $28K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,762 | $28K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 320 | $27K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,557 | $25K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,931 | $25K |
| 76830 | Ultrasound, transvaginal | <1% | 1,671 | $24K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 340 | $23K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 313 | $21K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 263 | $20K |
| 76813 | <1% | 552 | $19K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 700 | $18K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 156 | $18K |
| 73502 | <1% | 511 | $18K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 764 | $16K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 66 | $16K |
| 73130 | <1% | 1,147 | $16K | |
| 93271 | <1% | 47 | $15K | |
| 90677 | <1% | 396 | $15K | |
| 90656 | <1% | 2,615 | $15K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12,998 | $15K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 573 | $14K |
| 73610 | <1% | 1,272 | $14K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 428 | $13K |
| 92227 | <1% | 797 | $13K | |
| 0031A | <1% | 334 | $13K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,598 | $12K |
| 78451 | <1% | 107 | $12K | |
| 83921 | <1% | 375 | $12K | |
| 92504 | <1% | 795 | $12K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,011 | $12K |
| 11056 | <1% | 110 | $11K | |
| 97165 | <1% | 299 | $11K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 674 | $11K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 965 | $10K |
| 0154A | <1% | 252 | $9K | |
| 99220 | <1% | 51 | $8K | |
| 99397 | <1% | 28 | $8K | |
| 95806 | <1% | 61 | $8K | |
| 76536 | <1% | 114 | $8K | |
| 91200 | <1% | 259 | $8K | |
| 85027 | <1% | 4,098 | $8K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 40 | $8K |
| 90734 | <1% | 422 | $7K | |
| 90678 | <1% | 45 | $7K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 134 | $7K |
| 90651 | <1% | 694 | $7K | |
| 99173 | <1% | 14,966 | $7K | |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 875 | $7K |
| 90674 | <1% | 367 | $7K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 560 | $6K |
| 91319 | <1% | 288 | $6K | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 16,341 | $6K |
| 93296 | <1% | 105 | $6K | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 101 | $6K |
| 86360 | <1% | 110 | $6K | |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 257 | $5K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 144 | $5K |
| 72040 | <1% | 136 | $5K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 85 | $5K |
| 81002 | <1% | 2,078 | $5K | |
| 93016 | <1% | 102 | $5K | |
| 86359 | <1% | 110 | $5K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 44 | $5K |
| 97162 | <1% | 37 | $4K | |
| 76770 | <1% | 85 | $4K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 2,123 | $4K |
| 90694 | <1% | 39 | $4K | |
| 99177 | <1% | 3,975 | $4K | |
| 88141 | <1% | 410 | $4K | |
| 88342 | <1% | 125 | $4K | |
| 77065 | Tomosynthesis, mammo | <1% | 118 | $4K |
| 0051A | <1% | 100 | $4K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 295 | $4K |
| 90691 | <1% | 142 | $4K | |
| 90670 | <1% | 985 | $3K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 54 | $3K |
| 94060 | <1% | 42 | $3K | |
| 98968 | <1% | 182 | $3K | |
| 0074A | <1% | 89 | $3K | |
| 93018 | <1% | 101 | $3K | |
| 0052A | <1% | 74 | $3K | |
| 90715 | <1% | 262 | $3K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 94 | $3K |
| 0081A | <1% | 68 | $3K | |
| 92523 | <1% | 123 | $3K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 57 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 200 | $3K |
| 81329 | <1% | 133 | $2K | |
| 99201 | <1% | 402 | $2K | |
| 97010 | <1% | 624 | $2K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,008 | $2K |
| 72050 | <1% | 53 | $2K | |
| 93272 | <1% | 47 | $2K | |
| 0082A | <1% | 58 | $2K | |
| 91318 | <1% | 185 | $2K | |
| 90672 | <1% | 615 | $2K | |
| 99234 | <1% | 41 | $2K | |
| 73564 | <1% | 73 | $2K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 352 | $2K |
| 74018 | <1% | 256 | $2K | |
| 0112A | <1% | 51 | $2K | |
| 0013A | <1% | 49 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $2K |
| 99241 | <1% | 39 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $2K |
| 90648 | <1% | 1,409 | $2K | |
| 92587 | <1% | 303 | $2K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 305 | $2K |
| 99205 | Prolong outpt/office vis | <1% | 38 | $2K |
| 87338 | <1% | 974 | $2K | |
| 93288 | <1% | 12 | $2K | |
| 88307 | <1% | 66 | $2K | |
| 81003 | <1% | 1,735 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 53 | $1K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 36 | $1K |
| 0111A | <1% | 37 | $1K | |
| 11900 | <1% | 106 | $1K | |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 12 | $1K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 124 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 46 | $1K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 20 | $1K |
| 0003A | <1% | 35 | $1K | |
| 73110 | <1% | 245 | $1K | |
| 73140 | <1% | 173 | $1K | |
| 86580 | <1% | 634 | $1K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 40 | $1K |
| 90632 | <1% | 44 | $1K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 26 | $1K |
| 90710 | <1% | 26 | $1K | |
| 96112 | <1% | 80 | $1K | |
| 99417 | Prolong home eval add 15m | <1% | 76 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 139 | $1K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,801 | $997.79 |
| 90633 | <1% | 408 | $973.30 | |
| 88304 | <1% | 120 | $855.46 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 102 | $840.07 |
| 92579 | <1% | 134 | $827.79 | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 101 | $795.00 |
| 81025 | <1% | 485 | $785.14 | |
| 95117 | <1% | 88 | $758.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 766 | $737.49 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 66 | $693.00 |
| 90849 | <1% | 25 | $644.00 | |
| 72170 | <1% | 65 | $639.28 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 82 | $633.64 |
| 90723 | <1% | 478 | $632.53 | |
| 85014 | <1% | 269 | $623.00 | |
| 99051 | <1% | 17,384 | $604.72 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 431 | $592.47 |
| 73523 | <1% | 15 | $585.00 | |
| 90746 | <1% | 15 | $536.00 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 395 | $512.67 |
| 99307 | <1% | 123 | $495.10 | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 12 | $494.57 |
| 92235 | <1% | 17 | $457.24 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 22 | $378.18 |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 29 | $370.66 |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 99 | $320.00 |
| 73080 | <1% | 56 | $297.18 | |
| 73590 | <1% | 52 | $284.62 | |
| 90681 | <1% | 42 | $276.07 | |
| 0083A | <1% | 44 | $236.50 | |
| 82962 | <1% | 55 | $230.00 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 68 | $222.75 |
| 73560 | <1% | 16 | $207.13 | |
| 90660 | <1% | 77 | $190.00 | |
| 73100 | <1% | 12 | $185.00 | |
| 82274 | <1% | 13 | $183.82 | |
| 99310 | Prolong nursin fac eval 15m | <1% | 20 | $173.14 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 83 | $169.97 |
| 93971 | <1% | 26 | $158.89 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 15 | $150.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 62 | $145.50 |
| 90696 | <1% | 36 | $137.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 18 | $128.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 42 | $86.45 |
| 99188 | <1% | 40 | $80.00 | |
| 90658 | <1% | 248 | $78.91 | |
| 99221 | <1% | 13 | $65.17 | |
| 85046 | <1% | 62 | $60.00 | |
| 90655 | <1% | 37 | $56.00 | |
| 82985 | <1% | 13 | $52.92 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 34 | $31.15 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 32 | $23.23 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 32 | $8.80 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 13 | $0.42 |
| G9920 | Screening performed and negative | <1% | 6,206 | $0.06 |
| 1036F | 0% | 19,686 | $0.00 | |
| 99024 | 0% | 315 | $0.00 | |
| 3044F | 0% | 2,527 | $0.00 | |
| 80051 | 0% | 49 | $0.00 | |
| 90688 | 0% | 234 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 41 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 68 | $0.00 |
| 3052F | 0% | 147 | $0.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 98 | $0.00 |
| 83550 | 0% | 12 | $0.00 | |
| 82043 | 0% | 15 | $0.00 | |
| 99318 | 0% | 12 | $0.00 | |
| 82728 | 0% | 14 | $0.00 | |
| 84075 | 0% | 12 | $0.00 | |
| 99354 | 0% | 13 | $0.00 | |
| 3051F | 0% | 253 | $0.00 | |
| 3046F | 0% | 187 | $0.00 | |
| 82565 | 0% | 76 | $0.00 | |
| 87210 | 0% | 43 | $0.00 | |
| 90661 | 0% | 105 | $0.00 | |
| 84460 | 0% | 39 | $0.00 | |
| G9919 | Screening performed and positive and provision of recommendations | 0% | 72 | $0.00 |
| 90756 | 0% | 14 | $0.00 | |
| 90838 | 0% | 14 | $0.00 | |
| 90700 | 0% | 14 | $0.00 | |
| 77072 | 0% | 12 | $0.00 | |
| 80061 | Lipid panel | 0% | 29 | $0.00 |
| 85610 | 0% | 14 | $0.00 | |
| 83540 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAVIDOFF, RAMIN (EXECUTIVE MEDICAL DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.